Genmab A/S/€GMAB
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Genmab A/S
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics for the treatment of cancer. The company's core products include a range of proprietary technologies and therapeutic antibodies, most notably DARZALEX (daratumumab), which is used in the treatment of multiple myeloma. Genmab collaborates with various pharmaceutical companies to advance its research and expand its product offerings. Founded in 1999, the company leverages its proprietary antibody technologies, including the DuoBody and HexaBody platforms, to create differentiated therapies. Its strategic partnerships and emphasis on cutting-edge research provide it with a notable position in the biopharmaceutical industry.
Ticker
€GMAB
Sector
Primary listing
XGAT
Employees
2,639
Headquarters
Copenhagen, Denmark
Website
Genmab A/S Metrics
BasicAdvanced
€15B
13.47
€18.53
0.82
-
Price and volume
Market cap
€15B
Beta
0.82
52-week high
€286.90
52-week low
€154.81
Average daily volume
560
Financial strength
Current ratio
6.216
Quick ratio
6.196
Long term debt to equity
2.49
Total debt to equity
2.791
Interest coverage (TTM)
49.22%
Profitability
EBITDA (TTM)
1,137.999
Gross margin (TTM)
94.54%
Net profit margin (TTM)
37.59%
Operating margin (TTM)
34.95%
Effective tax rate (TTM)
11.77%
Revenue per employee (TTM)
€1,183,070
Management effectiveness
Return on assets (TTM)
13.26%
Return on equity (TTM)
28.12%
Valuation
Price to earnings (TTM)
13.472
Price to revenue (TTM)
5.04
Price to book
21.69
Price to tangible book (TTM)
36
Price to free cash flow (TTM)
17.429
Free cash flow yield (TTM)
5.74%
Free cash flow per share (TTM)
14.327
Growth
Revenue change (TTM)
32.97%
Earnings per share change (TTM)
77.72%
3-year revenue growth (CAGR)
31.40%
10-year revenue growth (CAGR)
40.59%
3-year earnings per share growth (CAGR)
31.80%
10-year earnings per share growth (CAGR)
33.13%
Bulls say / Bears say
Genmab is under legal pressure from AbbVie over alleged trade secret theft involving its ADC linker technology. This lawsuit led to a 3.8% drop in Genmab’s U.S. shares and may result in large damages or court injunctions, putting additional strain on the Rina-S pipeline and research costs (Reuters).
Investors reacted unfavorably to Genmab’s $8 billion buyout of Merus, as evidenced by a 4.1% decline in Genmab’s U.S.-listed shares on the day the deal was announced, reflecting doubts about the acquisition's value and concerns over Genmab's ability to successfully integrate the deal (Barron's).
Genmab plans to fund the Merus deal with around $5.5 billion in non-convertible debt, greatly increasing its leverage and potentially limiting its financial ability to invest in other pipeline projects (StockTitan).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genmab A/S stock?
Genmab A/S (GMAB) has a market cap of €15B as of October 29, 2025.
What is the P/E ratio for Genmab A/S stock?
The price to earnings (P/E) ratio for Genmab A/S (GMAB) stock is 13.47 as of October 29, 2025.
Does Genmab A/S stock pay dividends?
No, Genmab A/S (GMAB) stock does not pay dividends to its shareholders as of October 29, 2025.
When is the next Genmab A/S dividend payment date?
Genmab A/S (GMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Genmab A/S?
Genmab A/S (GMAB) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.